Mouse Models of Human Phenylketonuria
AUTOR(ES)
Shedlovsky, A.
RESUMO
Phenylketonuria (PKU) results from a deficiency in phenylalanine hydroxylase, the enzyme catalyzing the conversion of phenylalanine (PHE) to tyrosine. Although this inborn error of metabolism was among the first in humans to be understood biochemically and genetically, little is known of the mechanism(s) involved in the pathology of PKU. We have combined mouse germline mutagenesis with screens for hyperphenylalaninemia to isolate three mutants deficient in phenylalanine hydroxylase (PAH) activity and cross-reactive protein. Two of these have reduced PAH mRNA and display characteristics of untreated human PKU patients. A low PHE diet partially reverses these abnormalities. Our success in using high frequency random germline point mutagenesis to obtain appropriate disease models illustrates how such mutagenesis can complement the emergent power of targeted mutagenesis in the mouse. The mutants now can be used as models in studying both maternal PKU and somatic gene therapy.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1205587Documentos Relacionados
- Three mouse models of human thalassemia.
- Cerebral protein synthesis in a genetic mouse model of phenylketonuria
- Web-based access to mouse models of human cancers: the Mouse Tumor Biology (MTB) Database
- Mouse Models of Human Autoimmune Diseases: Essential Tools That Require the Proper Controls
- Complete suppression of in vivo growth of human leukemia cells by specific immunotoxins: nude mouse models.
